On March 6, 2014 the FDA approved isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis.
Here you can find the FDA press release
While the aspergillosis indication is based on a large, well-designed randomized clinical trial, the mucormycosis indication is based single arm study results compared to literature data and a comparison with results from the ECMM FungiScope registry. For ECMM this is a unprecedented success in this area.
Oliver A. Cornely
President of the ECMM